Signant Health has announced new audit trail reviewing and reporting functionality for its electronic clinical outcome assessment (eCOA) and remote sensor platform, TrialMax. This new functionality enables authorized personnel to access and explore key audit trail data through interactive reports and dashboards in just a few clicks. The efficiencies are realized through TrialMax’s ability to track user actions and inputs in real-time, creating a behind the scenes audit trail as users interact with the tool, and through leveraging Signant Health’s enterprise analytics platform.
Signant Health developed TrialMax’s latest audit features in consultation with users and clients responsible for clinical oversight and data management in order to ensure compliance with data integrity guidance and definitions from the FDA, EMA and MHRA. These latest features provide TrialMax users with:
This update comes in response to the ever-increasing demand from regulatory bodies on life science companies to put quality systems in place to ensure generation of high-integrity data for accurate drug evaluation. Enabling the detailed inspection of audit trail data is a regulatory compliance requirement, with audit trail deficiencies cited in a growing number of regulatory inspections.
“The proliferation of home-based remote sensors, eCOA, and other sources of patient data have increased the volume and variety of data captured in today’s trials, making data integrity monitoring more cumbersome than ever before”, comments Rauha Tulkki-Wilke, Senior Vice President, Product Management, Signant Health. “The TrialMax platform now offers enhanced audit trail reporting capabilities that enable sponsors and sites to fulfill regulatory and GCP requirements by inspecting the underlying audit history to ensure data integrity-made easy through the interactive reporting tools provided through TrialMax. This is a critical element in establishing the traceability and reliability of an electronic record.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.